Sirolimus rx in women: what the evidence actually shows

Last updated 2026-07-27

Does sirolimus work differently in women than in men?

Nobody has run a human trial designed to answer this, so the honest answer is: probably somewhat, based on mouse data, but nobody knows the size or direction of the effect in people. Sirolimus and rapamycin are the same drug (rapamycin is the generic name, sirolimus is the USAN/INN pharmaceutical name; Rapamune is the original Wyeth brand) ^[1]. The FDA approved it in 1999 to prevent organ transplant rejection, and later approvals cover Fyarro for a rare soft tissue sarcoma and Hyftor for facial angiofibromas in tuberous sclerosis ^[1]. None of those approvals are for aging or lifespan extension. That use is entirely off-label. The strongest lifespan evidence sits in mice, and it comes from the National Institute on Aging's Interventions Testing Program (ITP), which tests compounds across three labs using genetically heterogeneous mice, not inbred strains. The ITP's first rapamycin cohort, started late in life at roughly 600 days of age, found median lifespan extension of about 23% in females and about 26% in males compared to controls ^[2]. That's a real, replicated, dose-responsive effect. But 'about equal in both sexes' in that specific study is not the same as 'works identically in women.' Other ITP cohorts starting rapamycin earlier in life (at 9 months) found larger relative gains in females than males at certain doses, and dose-response curves have not been identical between sexes across every cohort ^[3]. The honest summary: sex matters in mice, the direction of the difference isn't consistent across every study, and translating any of it to a specific milligram dose in a 45-year-old woman is a guess, not a calculation.

Is there any human trial data on sirolimus and lifespan in women specifically?

No. There is no completed randomized controlled trial measuring lifespan or healthspan outcomes from sirolimus in humans of either sex, let alone one powered to detect a sex difference. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), run through AgelessRx, is the closest thing to a human dataset on low-dose intermittent rapamycin in a general population, and it enrolled adults using patient-reported outcomes over 48 weeks, not a lifespan endpoint, with a sizable share of female participants ^[4]. It is not FDA-reviewed, it wasn't designed as a registration trial, and its outcomes (frailty index components, patient-reported wellbeing) are a long way from 'lives longer.' Everything else you'll see cited as 'human evidence' is either transplant pharmacology (people on chronic, much higher, continuous doses for organ rejection, not intermittent low-dose protocols) or retrospective, uncontrolled reports from longevity clinics. If someone tells you sirolimus is 'proven' to extend life in women, they are overstating what exists. The mouse data is genuinely strong. The human lifespan data does not exist yet.

What do we know about sirolimus and the menstrual cycle or fertility?

Very little, and what exists is mostly about mTOR biology and animal reproduction studies, not clinical trials in reproductive-age women on low-dose protocols. Sirolimus is officially labeled as impairing fertility in animal studies. The Rapamune prescribing information states it can cause reduced fertility in male and female rats at doses used clinically in transplant patients, and it lists menstrual irregularities as an observed effect in transplant recipients on chronic sirolimus ^[5]. Separately, mTOR inhibition is being studied as a strategy to slow ovarian follicle depletion, the biological process behind reproductive aging. A small early-phase human study out of Columbia University's fertility research group is testing low-dose rapamycin in women specifically to see if it slows the rate of egg loss, using markers like AMH, not a lifespan endpoint . This is interesting and separate research, worth knowing about if you're a woman in your 30s or 40s interested in mTOR biology, but it is not the same claim as 'rapamycin extends female lifespan' and shouldn't be conflated with the longevity dosing protocols circulating online. If you are trying to conceive or could become pregnant, sirolimus is not something to self-start. Animal data show reproductive toxicity, and there is no human safety dataset for pregnancy exposure at any dose.

What are the real risks of off-label sirolimus use in women?

The three risks that show up most consistently in both transplant literature and longevity-clinic reports are immunosuppression, mouth ulcers (stomatitis), and metabolic changes, and none of them are sex-specific inventions, they just deserve a plain description. Immunosuppression is the mechanism, not a side effect to work around. Sirolimus works by inhibiting mTOR, a pathway central to immune cell proliferation. In transplant patients on continuous daily dosing, this shows up as higher infection risk, and the FDA label carries a boxed warning about increased susceptibility to infection and the possible development of lymphoma with chronic immunosuppression at transplant-level doses ^[5]. Intermittent, once-weekly, low-dose protocols used off-label for longevity are a different exposure pattern, and the ITP mouse data suggests this dosing style may separate lifespan benefit from immune suppression somewhat, but this hasn't been confirmed with human immune function studies at scale. Mouth ulcers (aphthous stomatitis) are the single most commonly reported side effect in every population that's taken sirolimus, transplant patients and longevity users alike. They tend to appear in the first few weeks, are dose-related, and often improve if the dose is lowered or the schedule spaced out. Metabolic effects include elevated LDL cholesterol and triglycerides, and in some patients, elevated blood glucose. These are listed adverse reactions in the Rapamune label from transplant trials ^[5] and are consistently reported anecdotally at lower off-label doses too, meaning anyone using this off-label should get baseline and follow-up lipid panels and fasting glucose, not skip them because the dose is 'low.' Wound healing impairment is also labeled, relevant if you have upcoming surgery or dental work planned ^[5].

Does sirolimus interact with hormone therapy or birth control?

This is understudied territory and worth flagging honestly rather than glossing over. Sirolimus is metabolized primarily by the CYP3A4 enzyme system, and the label specifically warns against combining it with strong CYP3A4 inhibitors or inducers, which changes sirolimus blood levels substantially ^[5]. Some hormonal contraceptives and hormone replacement formulations interact with CYP3A4 to varying degrees depending on the specific hormone and route. There is no dedicated clinical trial testing sirolimus alongside oral contraceptives or menopausal hormone therapy in a longevity-dosing context. Anyone on hormonal birth control, HRT, or considering starting either while using sirolimus off-label should discuss it explicitly with the prescriber managing the sirolimus regimen, not assume the interaction profile is negligible just because doses are lower than transplant protocols. This is exactly the kind of question a provider-reviewed prescribing relationship exists to catch, generic online dosing charts don't ask what else you're taking.

Are the side effects of sirolimus worse for women than men?

There's no large, controlled dataset comparing side effect rates by sex in a longevity-dosing population, so treat any specific claim ('women get more mouth ulcers' or similar) as anecdotal until better data exists. What we can say with more confidence: Body size and composition differ on average between men and women, and sirolimus dosing in transplant medicine is sometimes adjusted by body weight or therapeutic drug monitoring (blood trough levels), not a flat dose regardless of size ^[5]. Off-label longevity protocols that use a flat weekly milligram amount regardless of the person's weight are, by definition, not individualized the way clinical sirolimus dosing normally is. This matters more for smaller-framed people of either sex, who may end up with a relatively higher effective exposure at a 'standard' dose than a larger person would. Lipid effects (elevated cholesterol and triglycerides) deserve particular attention in women approaching or past menopause, since that transition already shifts lipid profiles independent of any drug, and stacking a known lipid-elevating medication on top of that biological shift is a reasonable thing to monitor closely with a lipid panel rather than ignore.

What dose of sirolimus do women use in off-label longevity protocols?

Reported protocols typically use once-weekly or twice-weekly dosing in the range of 3 to 6 mg per week, sometimes titrated based on blood trough levels drawn about a week after a dose, following the general dosing logic popularized by researchers studying intermittent rapamycin schedules in humans, adapted from Dr. Alan Green's and other longevity clinicians' published protocols and from the mouse ITP dosing patterns ^[2][3]. There is no dose specifically validated for women versus men in a controlled trial. Clinics that individualize by body weight and trough level are working from a more defensible starting point than anyone using a flat one-size-fits-all number pulled off a forum. If you want a structured starting point rather than guesswork, see our Sirolimus Rx dosage guide and the Sirolimus Rx dosage calculator, and talk through your specific labs and history with a prescriber before starting, rather than copying a number from someone else's protocol post.

Should women take sirolimus differently during perimenopause or menopause?

There is no dedicated clinical trial answering this, and anyone claiming a specific menopause-adjusted protocol is proven is overstating the evidence. What's true is that perimenopause and menopause bring their own lipid, bone density, and metabolic shifts, and layering a drug known to raise LDL and triglycerides on top of that transition is a reasonable thing to discuss with a physician who can see your actual labs, not a generic internet dosing chart. Some longevity clinicians reduce dose or extend the interval between doses in women reporting more pronounced side effects around this life stage, but this is clinical judgment applied case by case, not a validated protocol backed by trial data. If you're in this age range and considering sirolimus, get a baseline lipid panel, fasting glucose or A1c, and a conversation about your personal cardiovascular risk factors before starting, and repeat labs periodically rather than a single check at baseline.

How does this compare to what we know about sirolimus in men?

The mouse data is the cleanest comparison point we have, and it shows the effect exists in both sexes but isn't perfectly matched in size across every study design. | Data source | Finding in females | Finding in males |

What should a woman ask her doctor before starting sirolimus off-label?

Bring up your full reproductive history and current plans (pregnancy, hormonal contraception, HRT), your lipid panel and family cardiovascular history, any history of frequent mouth ulcers, and your current medication list checked specifically against CYP3A4 interactions ^[5]. Ask what blood monitoring schedule they'll use (trough levels, lipid panel, glucose, complete blood count) and how often. Ask them directly: 'what would make you stop this prescription.' A provider who can't answer that isn't the one who should be writing it. This is also where the practical mechanics matter: reconstitution, injection technique, and site rotation aren't things to improvise from a video. See how to reconstitute Sirolimus Rx, Sirolimus Rx how to inject, and Sirolimus Rx injection sites for the mechanics, and Sirolimus Rx cycle length for how long typical off-label cycles run before a break or lab recheck. None of that replaces an actual prescribing relationship. Sirolimus Rx works through provider-reviewed prescribing with fulfillment through a licensed U.S. compounding pharmacy partner, which is a meaningfully different starting point than an unregulated overseas source with no clinician oversight at all.

Frequently asked questions

Is sirolimus the same as rapamycin?

Yes. Rapamycin is the original generic name for the compound discovered on Easter Island; sirolimus is the pharmaceutical (USAN/INN) name used on FDA labeling and prescriptions. Rapamune is the original brand name. All refer to the same molecule, so 'sirolimus' and 'rapamycin' can be used interchangeably in almost every context you'll encounter.

Has sirolimus been proven to extend lifespan in women?

No human trial has measured lifespan outcomes from sirolimus in women or men. The strongest evidence is in mice, where the NIA Interventions Testing Program found roughly 23% median lifespan extension in females and 26% in males in one cohort ^[2]. Translating that to a proven human effect, in either sex, has not been done.

Does sirolimus affect fertility in women?

The FDA label for Rapamune notes reduced fertility in female and male rats at clinically relevant doses and lists menstrual irregularities in transplant patients on chronic sirolimus ^[5]. There's no clinical trial on fertility effects at low-dose intermittent longevity protocols specifically, so treat this as an open question, not a settled negative.

Can sirolimus be taken with birth control or hormone replacement therapy?

There's no dedicated interaction trial. Sirolimus is metabolized by CYP3A4, and some hormonal contraceptives and HRT formulations affect that same enzyme system, which can change sirolimus blood levels ^[5]. Discuss your specific hormonal medication with the prescriber managing your sirolimus dose rather than assuming no interaction.

What are the most common side effects women report on sirolimus?

Mouth ulcers (stomatitis), elevated LDL cholesterol and triglycerides, and in some cases elevated blood glucose are the most consistently reported effects across transplant literature and off-label longevity use ^[5]. These aren't sex-specific findings, they show up in men too, but they're worth monitoring with regular labs regardless of dose.

Is low-dose intermittent sirolimus safer than transplant-dose sirolimus?

It appears to carry less immune suppression risk based on mouse and mechanistic reasoning, since intermittent low dosing is designed to hit mTORC1 without the sustained trough levels used in transplant medicine. But this hasn't been confirmed with large human immune-function studies, so 'safer' is a reasonable hypothesis, not an established fact.

Does age matter for women considering sirolimus, like starting in your 30s versus your 50s?

There's no human data establishing an optimal starting age for either sex. Mouse ITP studies show benefit even when rapamycin is started later in life (around 600 days, roughly equivalent to late-middle-age in mice), which is notable, but mouse aging biology and human aging biology aren't identical, so age-specific human guidance doesn't exist yet ^[2].

Can pregnant or breastfeeding women take sirolimus?

This should not be self-directed. Animal studies show reproductive toxicity, and there is no human safety database for pregnancy or lactation exposure at any dose level ^[5]. Anyone who is pregnant, trying to conceive, or breastfeeding should discuss this directly and specifically with a physician before considering sirolimus in any form.

What labs should women get before and during sirolimus use?

A reasonable baseline includes a fasting lipid panel, fasting glucose or A1c, complete blood count, and kidney and liver function. Many prescribers also check sirolimus trough blood levels about a week after a dose to guide titration. Repeat labs periodically, more than at baseline, since lipid and glucose effects can develop over months.

Is there a women-specific sirolimus dosing protocol backed by research?

No validated, trial-tested women-specific protocol exists. Some clinicians adjust dose or interval based on body weight, trough levels, and individual side effect reports, which is reasonable clinical practice, but it isn't the same as a protocol proven in a controlled study specifically for women.

Why is mTOR inhibition being studied for ovarian aging separately from longevity dosing?

A small early study out of Columbia University's fertility research program is testing whether low-dose rapamycin slows the rate of ovarian follicle loss, tracked via markers like AMH ^[6]. This is a distinct research question from lifespan extension and uses different endpoints, so it shouldn't be cited as proof of a longevity benefit.

Where can women get sirolimus prescribed legitimately for off-label use?

Sirolimus requires a prescription in the United States; it isn't sold over the counter or legitimately through unregulated overseas sellers. Sirolimus Rx connects patients with provider-reviewed prescribing and fulfillment through a licensed U.S. compounding pharmacy partner, which is a materially different safety setup than sourcing it without any clinician involved.

Sources

1. FDA, Rapamune (sirolimus) drug approval and label history: Sirolimus (Rapamune) was FDA approved in 1999 for transplant rejection prophylaxis; sirolimus and rapamycin are the same molecule
2. Harrison et al., Nature 2009, NIA Interventions Testing Program rapamycin cohort: Rapamycin extended median lifespan by approximately 23% in female and 26% in male mice when started around 600 days of age
3. Miller et al., Journals of Gerontology Series A, NIA ITP dose and sex comparison data: Rapamycin dose-response and sex differences vary across ITP cohorts depending on starting age and dose
4. PEARL Trial (AgelessRx), Participatory Evaluation of Aging with Rapamycin for Longevity: The PEARL trial is a human study of low-dose intermittent rapamycin measuring patient-reported healthspan outcomes over 48 weeks, not a lifespan endpoint
5. Goldman et al., Columbia University, low-dose rapamycin and ovarian reserve pilot study, ClinicalTrials.gov: Early-phase human research is testing low-dose rapamycin's effect on ovarian follicle depletion using markers such as AMH